Literature DB >> 10533870

Differences in lung bioavailability between different propellants for fluticasone propionate.

A M Wilson, E J Sims, L C Orr, B J Lipworth.   

Abstract

The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10533870     DOI： 10.1016/S0140-6736(99)03581-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  4 in total

1.  Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.

Authors:  S J Fowler; L C Orr; A M Wilson; E J Sims; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

Review 2.  Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

Authors:  B J Lipworth; C M Jackson
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

3.  Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma.

Authors:  Graeme P Currie; Suvi Stenback; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

4.  Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.

Authors:  G P Currie; S J Fowler; A M Wilson; E J Sims; L C Orr; B J Lipworth
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.